![[D-Arg1,D-Trp5,7,9,Leu11]-Substance P](https://file.medchemexpress.com/product_pic/hy-p11405.gif "Click to View [D-Arg1,D-Trp5,7,9,Leu11]-Substance P Product Detail")
Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
6527 Results for "
models
" in MedChemExpress (MCE) Product Catalog:
Products (6527)
6527 Results for "models" in MCE Product Catalog:
Cat. No.: HY-183144
CAS No.: 141575-50-0
Target:
Research Areas:
Vedaclidine is an orally active muscarinic acetylcholine receptor (mAChR) modulator with mixed receptor activity, which activates muscarinic M2 and M4 receptors and blocks muscarinic M1, M3 and M5 receptors. Vedaclidine exerts its activity through interaction with spinal M4 muscarinic receptors, and does not induce hypothermia or excessive salivation. Vedaclidine can be used in research related to pain, neuropathic pain and inflammatory pain states .
Cat. No.: HY-183409
CAS No.: 1941243-22-6
Synonyms: ONO-5450598
Target:
Research Areas:
ONO-7684 (ONO-5450598) is an orally active coagulation factor XIa (FXIa) inhibitor with a Ki value of 2 nM against human FXIa. ONO-7684 inhibits human FXIa in a competitive and reversible manner, reduces factor XI coagulation activity, prolongs activated partial thromboplastin time in a dose-dependent manner, and exerts no significant effects on PT/INR and the activity of related serine proteases. ONO-7684 exerts antithrombotic effects in vivo without prolonging bleeding time. ONO-7684 can be used in studies related to thromboembolic diseases .
Cat. No.: HY-183773
Target:
Research Areas:
KOR agonist-9 is a selective kappa opioid receptor (KOR) agonist with an EC50 of 1.41 nM. KOR agonist-9 exhibits >125-fold selectivity over μ/δ-opioid receptors. KOR agonist-9 antinociceptive and antipruritic effects in mice. KOR agonist-9 can be used for the research of pain, pruritus .
Cat. No.: HY-184266
CAS No.: 2926699-71-8
Synonyms: ONO-6428513
Target:
Research Areas:
GCLCi0 (ONO-6428513) is a glutamate-cysteine ligase catalytic subunit (GCLC) inhibitor and ferroptosis inducer that blocks the rate-limiting step of glutathione synthesis and exerts anti-tumor activity. GCLCi0 specifically targets SMARCB1-deficient cancer cells, induces reactive oxygen species production and lipid peroxidation. In addition, GCLCi0 shows a significant synergistic effect with SLC7A11 inhibitors and Telaglenastat (HY-12248). GCLCi0 can be used in the research of smarcb1-deficient malignant rhabdoid tumors and smarcb1-deficient epithelioid sarcomas .
Cat. No.: HY-185484
Synonyms: BMS-936561
Research Areas:
MDX-1203 (BMS-936561) is an antibody-drug conjugate targeting CD70. MDX-1203 binds to CD70 and mediates the specific delivery of its conjugated cytotoxic payload to tumors. MDX-1203 delivers a DNA alkylating payload into cells. MDX-1203 can be used in research related to advanced clear cell renal cell carcinoma and relapsed/refractory B-cell non-Hodgkin lymphoma .
Cat. No.: HY-189221
Antimicrobial agent-56 is an antimicrobial agent that targets the cell membrane of drug-resistant bacteria. Antimicrobial agent-56 disrupts the cell membrane integrity of methicillin-resistant Staphylococcus aureus (MRSA) via membrane targeting, downregulates lipoteichoic acid biosynthesis and two-component system signaling, inhibits MRSA biofilm formation and eradicates mature biofilms, with a MIC of 6.25 μg/mL. Antimicrobial agent-56 hardly induces drug resistance, exhibits low hemolytic activity, inhibits NO production stimulated by LPS (HY-D1056), and retains the anti-inflammatory activity of Resveratrol (HY-16561). Antimicrobial agent-56 loaded in PVA-SA hydrogel promotes the healing of MRSA-infected wounds and suppresses inflammation. Antimicrobial agent-56 can be used in studies related to MRSA infections .
Cat. No.: HY-P11259
CAS No.: 3090687-02-5
Target:
Research Areas:
Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Cat. No.: HY-P11405
CAS No.: 122481-75-8
Target:
Research Areas:
Cat. No.: HY-P11430
CAS No.: 290360-66-6
Target:
Research Areas:
Cat. No.: HY-P11928
CAS No.: 3121532-43-9
Cat. No.: HY-P1907
CAS No.: 151812-18-9
Research Areas:
Glutaminase (GLS) is a metabolic enzyme. Glutaminase catalyzes the conversion of glutamine to glutamate, which is a key step in glutaminolysis. The glutaminase isoenzymes GLS and GLS2 differ in their expression patterns and functional roles: GLS exhibits oncogenic properties, whereas GLS2 is regarded as a tumor suppressor. Glutaminase expression levels correlate with the degree of tumor malignancy .
Cat. No.: HY-P4096A
Target:
Research Areas:
Cat. No.: HY-P991902
Cat. No.: HY-W050154R
CAS No.: 501-30-4
Category:
Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite
Target:
Cat. No.: HY-181163
Research Areas:
Caspase-3/7 activator 4 is a caspase-3 activator and caspase-7 activator. Caspase-3/7 activator 4 inhibits key enzymes in estrogen biosynthesis, including aromatase (IC50 = 38.3 nM) and steroid sulfatase (IC50 = 12.7 µM), and selectively suppresses COX-2 (IC50 = 5.38 µM). Caspase-3/7 activator 4 shows strong antioxidant activity (DPPH: IC50 = 16.26 µM). Caspase-3/7 activator 4 inhibits estrogen synthesis, suppresses estrogen availability, reduces prostaglandin production, increases caspase-3/7 expression, induces G0/G1 cell cycle arrest, induces apoptotic cell death, reduces circulating TNF-α and VEGFR-II levels, restores hepatorenal function markers and histoarchitecture, restores antioxidant defense enzyme activity, reduces lipid peroxidation, exerts antiproliferative activity against breast cancer cells, exerts antitumor activity in the Ehrlich ascites carcinoma models. Caspase-3/7 activator 4 can be used for the research of breast cancer, ehrlich ascites carcinoma .
Cat. No.: HY-N0113BR
CAS No.: 6027-23-2
Synonyms: Ordenina hydrochloride (Standard); Peyocactine hydrochloride (Standard)
Category:
Coryphantha vivipara var arizonica Alkaloids Monophenols Cactaceae Other Alkaloids Phenols Plants
Target:
Reference Standards Bacterial p38 MAPK JNK ERK Akt Interleukin Related TNF Receptor NO Synthase COX Reactive Oxygen Species (ROS) Microphthalmia Associated Transcription Factor (MITF) Wnt β-catenin Dopamine Receptor Adrenergic Receptor 5-HT Receptor Serotonin Transporter Dopamine Transporter α-synuclein
Cat. No.: HY-N0113BS
Synonyms: Ordenina-d6 hydrochloride; Peyocactine-d6 hydrochloride
Target:
Isotope-Labeled Compounds Bacterial p38 MAPK JNK ERK Akt Interleukin Related TNF Receptor NO Synthase COX Reactive Oxygen Species (ROS) Microphthalmia Associated Transcription Factor (MITF) Wnt β-catenin Dopamine Receptor Adrenergic Receptor 5-HT Receptor Serotonin Transporter Dopamine Transporter α-synuclein
Research Areas:
Hordenine-d6 hydrochloride (Ordenina-d6 hydrochloride; Peyocactine-d6 hydrochloride) is the deuterated-labeled Hordenine hydrochloride (HY-N0113B). Hordenine hydrochloride (Ordenina hydrochloride; Peyocactine hydrochloride) is a multifunctional alkaloid with oral activity and blood-brain barrier penetration. Hordenine hydrochloride inhibits LPS-induced phosphorylation of p38, JNK, ERK1/2, p65, IκB, and AKT, prevents p65 nuclear translocation, and suppresses inflammatory cytokines and mediators. Hordenine hydrochloride inhibits melanin synthesis in melanocytes and reconstructed epidermis. Hordenine hydrochloride activates the Wnt/β-catenin signaling pathway. Hordenine hydrochloride activates DRD2, acts as a D3R partial agonist, α2A-AR full agonist, and 5-HT2A-R antagonist, and inhibits SERT and DAT. Hordenine hydrochloride inhibits α-synuclein accumulation and ameliorates motor deficits in Parkinson's disease models. Hordenine hydrochloride limits alcohol intake, reduces relapse drinking behavior. Hordenine hydrochloride can be used for research on mastitis, skin pigmentation, acute lung injury, foodborne diseases, hair loss, Parkinson's disease, bacterial infections, and alcohol use disorder .
Cat. No.: HY-W015490S
CAS No.: 26473-08-5
Cat. No.: HY-L948
11,491 compounds
PD-1/PD-L1 are key immune checkpoint targets that suppress T-cell-mediated anti-tumor immunity, representing a major focus in cancer immunotherapy. While antibody drugs dominate the clinic, they are limited by administration challenges and immune-related side effects. Small-molecule PD-1/PD-L1 inhibitors, with oral availability, good tissue penetration and low cost, have emerged as a promising next-generation strategy.
A PD-1/PD-L1 lead-like library was built via a five-step virtual screening process. After collecting 8,947 inhibitors from BindingDB and PubChem and filtering by activity and duplicates, AI similarity screening was performed using GeminiMol. Key pharmacophores were extracted from the PPI interface of co-crystal structures, and molecular was screened via a pharmacophore model, effectively enhancing target activity.
Containing 10,000 structurally diverse and drug-like molecules well-matched to the PD-L1 pocket, the library supports virtual docking, high-throughput screening and hit discovery, enabling efficient and rapid development of small-molecule immunotherapies.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
